KRAS and Pleural effusion: This manuscript reports a case of a patient with advanced NSCLC with pleural effusion and KRAS mutations treated poorly with conventional chemotherapy who had long‐term (more than 18 months) benefit with immunotherapy combined with an anti‐angiogenic inhibitor in Shanghai General Hospital.